REPONEX PHARMACEUTICALS A/S
Credit rating
Company information
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S (CVR number: 30082346K) is a company from HØRSHOLM. The company recorded a gross profit of 0 kDKK in 2023. The operating profit was -16.6 mDKK, while net earnings were -14.3 mDKK. The profitability of the company measured by Return on Assets (ROA) was -76.6 %, which can be considered poor and Return on Equity (ROE) was -80.4 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 77.4 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. REPONEX PHARMACEUTICALS A/S's liquidity measured by quick ratio was 1.6 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
Financial information
See financialsGross profit (kDKK)
EBIT (kDKK)
Profitability
Solidity
Key figures (kDKK)
See financials2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Volume | |||||
Net sales | |||||
Gross profit | |||||
EBIT | -2 337.66 | -2 302.03 | -12 603.84 | -11 277.00 | -16 600.00 |
Net earnings | -1 853.92 | -1 504.90 | -9 883.16 | -9 444.00 | -14 346.00 |
Shareholders equity total | 14 933.34 | 13 428.44 | 27 371.23 | 18 911.00 | 16 757.00 |
Balance sheet total (assets) | 17 501.73 | 20 408.87 | 28 708.18 | 21 516.00 | 21 662.00 |
Net debt | -2 537.91 | - 135.75 | -11 403.25 | -2 830.00 | -1 938.00 |
Profitability | |||||
EBIT-% | |||||
ROA | -17.2 % | -12.1 % | -51.3 % | -44.9 % | -76.6 % |
ROE | -21.4 % | -10.6 % | -48.4 % | -40.8 % | -80.4 % |
ROI | -30.3 % | -17.9 % | -63.9 % | -48.0 % | -90.1 % |
Economic value added (EVA) | -1 384.99 | - 595.79 | -8 685.75 | -9 727.58 | -14 263.67 |
Solvency | |||||
Equity ratio | 85.3 % | 71.0 % | 95.3 % | 87.9 % | 77.4 % |
Gearing | |||||
Relative net indebtedness % | |||||
Liquidity | |||||
Quick ratio | 3.1 | 0.4 | 11.8 | 3.1 | 1.6 |
Current ratio | 3.8 | 0.6 | 12.8 | 3.1 | 1.6 |
Cash and cash equivalents | 2 537.91 | 135.75 | 11 403.25 | 2 830.00 | 1 938.00 |
Capital use efficiency | |||||
Trade debtors turnover (days) | |||||
Net working capital % | |||||
Credit risk | |||||
Credit rating | BBB | BB | BB | BB | BB |
Variable visualization
Roles
Companies in the same industry
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.